Browsing Tag
Daiichi Sankyo
33 posts
TROPION-PanTumor03 trial reports breakthrough responses with DATROWAY and Rilvegostomig combo in bladder cancer
Discover how DATROWAY plus rilvegostomig is rivaling the EV-302 standard with high response rates in metastatic urothelial cancer.
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ: AZN) surge on Datroway’s historic first-line TNBC survival win
Find out how Datroway’s first-line TNBC survival win could rewrite chemotherapy-first playbooks and accelerate the ADC era in breast cancer—read the full analysis.
Can ifinatamab deruxtecan redefine treatment for late-stage small cell lung cancer? Here’s what the trial shows
Discover how ifinatamab deruxtecan delivered a 48% objective response rate in pretreated ES-SCLC. Read on for trial results and next steps.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
HER3-DXd shows promise in treating brain metastases: Inside the TUXEDO-3 trial results from ASCO 2025
HER3-DXd from Daiichi Sankyo and Merck shows intracranial activity in CNS cancers, as TUXEDO-3 results presented at ASCO 2025 spark major oncology interest.
EU approves Enhertu as first HER2-targeted therapy for HR-positive, HER2-low metastatic breast cancer
Discover how Enhertu’s EU approval is transforming care for HR-positive, HER2-low and HER2-ultralow breast cancer, and what it means for AstraZeneca’s future.
AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge…
Roche secures FDA approval for HER2-ultralow metastatic breast cancer diagnostic
Roche has received FDA approval for an expanded use of its PATHWAY HER2 (4B5) test, marking a significant…
ENHERTU gains FDA approval for HER2 low or ultralow metastatic breast cancer treatment
Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured approval from the U.S. Food and Drug Administration (FDA)…
Datroway approved in US: A new era in metastatic breast cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class…